Forest Raises $1.8 Billion in Bond Sale to Fund Aptalis Takeover

Forest Laboratories Inc. (FRX), the maker of the Alzheimer’s drug Namenda, raised $1.8 billion with a two-part bond offering to fund the takeover of Aptalis Pharma, more than doubling its debt.

Forest sold $1.05 billion of 4.375 percent notes due in five years to yield 277 basis points more than similar-maturity Treasuries and $750 million of 4.875 percent bonds maturing in 2021 to yield 267 basis points more than benchmarks, according to data compiled by Bloomberg. Standard & Poor’s rates the New York-based company BB+.

Its shares have rallied 11 percent since Forest announced the $2.9 billion takeover Jan. 8. The company is seeking new products after the loss of patent protection for its former top-seller, the antidepressant Lexapro. It’s the first buyout at Forest for Chief Executive Officer Brent Saunders, who took over Oct. 1 after proxy battles between the company and billionaire investor Carl Icahn, who gained a board seat in 2012.

The offering more than doubles the company’s $1.2 billion of debt. Its 5 percent securities due December 2021 were quoted at 101.4 cents on the dollar Jan. 24, Bloomberg prices show.

The pharmaceutical industry has been struggling to replace revenue lost to generic-drug competitors as patents expired in recent years for medicines including Pfizer Inc.’s Lipitor and Bristol-Myers Squibb Co.’s Singulair. More than $60 billion was lost to generics from 2010 to 2012, according to research by analysts at Bloomberg Industries.

Forest shares climbed 0.3 percent to $65.14 in New York trading.

To contact the reporter on this story: Matt Robinson in New York at

To contact the editor responsible for this story: Shannon D. Harrington at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.